Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study
RCT 91 hospitalized patients in Colombia showing shorter time to discharge with convalescent plasma, but higher mortality (without statistical significance).
risk of death, 220.0% higher, HR 3.20, p = 0.16, treatment 46, control 45, Cox proportional hazards.
|
risk of no hospital discharge, 37.5% lower, HR 0.62, p = 0.04, treatment 46, control 45, inverted to make HR<1 favor treatment, Cox proportional hazards.
|
risk of no viral clearance, 25.0% higher, OR 1.25, p = 0.72, treatment 46, control 45, adjusted per study, mid-recovery, day 4, RR approximated with OR.
|
risk of no viral clearance, 16.0% higher, OR 1.16, p = 0.82, treatment 46, control 45, adjusted per study, day 7, RR approximated with OR.
|
risk of no viral clearance, 51.0% higher, OR 1.51, p = 0.60, treatment 46, control 45, adjusted per study, day 14, RR approximated with OR.
|
risk of no viral clearance, 12.0% higher, OR 1.12, p = 0.91, treatment 46, control 45, adjusted per study, day 28, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Rojas et al., 27 Jun 2022, Single Blind Randomized Controlled Trial, Colombia, peer-reviewed, 45 authors, study period 8 August, 2020 - 13 November, 2020, average treatment delay 11.0 days, trial
NCT04332835 (history).
Contact:
anayajm@gmail.com (corresponding author).
Abstract: (2022) 22:575
Rojas et al. BMC Infectious Diseases
https://doi.org/10.1186/s12879-022-07560-7
Open Access
RESEARCH
Safety and efficacy of convalescent plasma
for severe COVID‑19: a randomized, single
blinded, parallel, controlled clinical study
Manuel Rojas1,2, Yhojan Rodríguez3, Juan Carlos Hernández4, Juan C. Díaz‑Coronado5,
José Alejandro Daza Vergara6, Verónica Posada Vélez7, Jessica Porras Mancilla7, Iván Araujo5, Jairo Torres Yepes6,
Oscar Briceño Ricaurte6, Juan Mauricio Pardo‑Oviedo6, Diana M. Monsalve3, Yeny Acosta‑Ampudia3,
Carolina Ramírez‑Santana3, Paula Gaviria García8, Lina Acevedo Landinez8, Luisa Duarte Correales8,
Jeser Santiago Grass8, Cristian Ricaurte Pérez8, Gustavo Salguero López8, Nataly Mateus4, Laura Mancera4,
Ronald Rengifo Devia4, Juan Esteban Orjuela4, Christian R. Parra‑Moreno4, Andrés Alfonso Buitrago4,
Inés Elvira Ordoñez4, Claudia Fabra Osorio7, Nathalia Ballesteros9, Luz H. Patiño9, Sergio Castañeda9,
Marina Muñoz9, Juan David Ramírez9,10, Paul Bastard11,12,13,14, Adrian Gervais13,15, Lucy Bizien13,15,
Jean‑Laurent Casanova12,13,14,16,17,18, Bernardo Camacho8, Juan Esteban Gallo19, Oscar Gómez19,
Adriana Rojas‑Villarraga20, Carlos E. Pérez21, Rubén Manrique22, Rubén D. Mantilla3 and Juan‑Manuel Anaya3,23*
Abstract
Background: Convalescent plasma (CP) has been widely used to treat COVID-19 and is under study. However, the
variability in the current clinical trials has averted its wide use in the current pandemic. We aimed to evaluate the
safety and efficacy of CP in severe coronavirus disease 2019 (COVID-19) in the early stages of the disease.
Methods: A randomized controlled clinical study was conducted on 101 patients admitted to the hospital with
confirmed severe COVID-19. Most participants had less than 14 days from symptoms onset and less than seven days
from hospitalization. Fifty patients were assigned to receive CP plus standard therapy (ST), and 51 were assigned to
receive ST alone. Participants in the CP arm received two doses of 250 mL each, transfused 24 h apart. All transfused
plasma was obtained from "super donors" that fulfilled the following criteria: titers of anti-SARS-CoV-2 S1 IgG ≥ 1:3200
and IgA ≥ 1:800 antibodies. The effect of transfused anti-IFN antibodies and the SARS-CoV-2 variants at the entry of
the study on the overall CP efficacy was evaluated. The primary outcomes were the reduction in viral load and the
increase in IgG and IgA antibodies at 28 days of follow-up. The per-protocol analysis included 91 patients.
Results: An early but transient increase in IgG anti-S1-SARS-CoV-2 antibody levels at day 4 post-transfusion was
observed (Estimated difference [ED], − 1.36; 95% CI, − 2.33 to − 0.39; P = 0.04). However, CP was not associated with
viral load reduction in any of the points evaluated. Analysis of secondary outcomes revealed that those patients in the
CP arm disclosed a shorter time to discharge (ED adjusted for mortality, 3.1 days; 95% CI, 0.20 to 5.94; P = 0.0361) or a
reduction of 2 points on the WHO scale when compared with the ST group (HR adjusted for mortality, 1.6; 95% CI, 1.03
*Correspondence: anayajm@gmail.com
23
Present Address: LifeFactors, Rionegro, Colombia
Full list of author information is available at the end of the article
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit